Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 58

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice

Bittolo, Tamara, Raminelli, Carlo Antonio, Deiana, Chiara, Baj, Gabriele, Vaghi, Valentina, Ferrazzo, Sara, Bernareggi, Annalisa, Tongiorgi, Enrico · 2016 · Scientific Reports

Abstract

Loss of MeCP2 (Methyl CpG binding protein 2) in Rett syndrome (RTT) causes brain weight decrease, shrinkage of the cortex with reduced dendritic arborization, behavioral abnormalities, seizures and cardio-respiratory complications. The observed monoamine neurotransmitters reduction in RTT suggested antidepressants as a possible therapy. We treated MeCP2-null mice from postnatal-day 28 for two weeks with desipramine, already tested in RTT, or mirtazapine, an antidepressant with limited side-effects, known to promote GABA release. Mirtazapine was more effective than desipramine in restoring somatosensory cortex thickness by fully rescuing pyramidal neurons dendritic arborization and spine density. Functionally, mirtazapine treatment normalized heart rate, breath rate, anxiety levels and eliminated the hopping behavior observed in MeCP2-null mice, leading to improved phenotypic score. These morphological and functional effects of mirtazapine were accompanied by reestablishment of the GABAergic and glutamatergic receptor activity recorded in cortex and brainstem tissues. Thus, mirtazapine can represent a new potential pharmacological treatment for the Rett syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep19796

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 46

  1. Amir, R. E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23, 185–188 (1999). · DOI · Paper page
  2. Belichenko, N. P., Belichenko, P. V., Li, H. H., Mobley, W. C. & Francke, U. Comparative study of brain morphology in Mecp2 mutant mouse models of Rett syndrome. J Comp Neurol 508, 184–195 (2008). · DOI
  3. Zoghbi, H. Y., Percy, A. K., Glaze, D. G., Butler, I. J. & Riccardi, V. M. Reduction of biogenic amine levels in the Rett syndrome. N Engl J Med 313, 921–924 (1985). · DOI
  4. Santos, M. et al. Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome. Neuroscience 170, 453–467 (2010). · DOI
  5. Roux, J. C., Dura, E., Moncla, A., Mancini, J. & Villard, L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci 25, 1915–1922 (2007). · DOI
  6. Amitai, Y. & Frischer, H. Excess fatality from desipramine in children and adolescents. J Am Acad Child Adolesc Psychiatry 45, 54–60 (2006). · DOI
  7. Walsh, B. T., Giardina, E. G., Sloan, R. P., Greenhill, L. & Goldfein, J. Effects of desipramine on autonomic control of the heart. J Am Acad Child Adolesc Psychiatry 33, 191–197 (1994). · DOI
  8. Burrows, G. D. & Kremer, C. M. Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol 17 Suppl 1, 34S–39S (1997). · DOI
  9. Hartmann, P. M. Mirtazapine: a newer antidepressant. Am Fam Physician 59, 159–161 (1999).
  10. Borkowska, A., Drozdz, W., Ziolkowska-Kochan, M. & Rybakowski, J. Enhancing effect of mirtazapine on cognitive functions associated with prefrontal cortex in patients with recurrent depression. Neuropsychopharmacol Hung 9, 131–136 (2007).
  11. Stenberg, J. H. et al. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35, 1080–1086 (2011). · DOI
  12. Katz, D. M. et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech 5, 733–745 (2012). · DOI · Paper page
  13. Lavergne, F., Berlin, I., Gamma, A., Stassen, H. & Angst, J. Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. Neuropsychiatr Dis Treat 1, 59–68 (2005). · DOI
  14. Rohdin, M. et al. Disturbances in cardiorespiratory function during day and night in Rett syndrome. Pediatr Neurol 37, 338–344 (2007). · DOI
  15. Walf, A. A. & Frye, C. A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2, 322–328 (2007). · DOI · Paper page
  16. Samaco, R. C., Hogart, A. & LaSalle, J. M. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum Mol Genet 14, 483–492 (2005). · DOI · Paper page
  17. Zhang, Z. W., Zak, J. D. & Liu, H. MeCP2 is required for normal development of GABAergic circuits in the thalamus. J Neurophysiol 103, 2470–2481 (2010). · DOI
  18. Miledi, R., Eusebi, F., Martinez-Torres, A., Palma, E. & Trettel, F. Expression of functional neurotransmitter receptors in Xenopus oocytes after injection of human brain membranes. Proc Natl Acad Sci USA 99, 13238–13242 (2002). · DOI
  19. Bernareggi, A., Duenas, Z., Reyes-Ruiz, J. M., Ruzzier, F. & Miledi, R. Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. Proc Natl Acad Sci USA 104, 2956–2960 (2007). · DOI
  20. Yamada, K. A. & Tang, C. M. Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents. J Neurosci 13, 3904–3915 (1993). · DOI · Paper page
  21. Limon, A., Reyes-Ruiz, J. M. & Miledi, R. Microtransplantation of neurotransmitter receptors from postmortem autistic brains to Xenopus oocytes. Proc Natl Acad Sci USA 105, 10973–10977 (2008). · DOI
  22. Mohandas, T., Sparkes, R. S. & Shapiro, L. J. Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation. Science 211, 393–396 (1981). · DOI · Paper page
  23. Belichenko, P. V., Hagberg, B. & Dahlstrom, A. Morphological study of neocortical areas in Rett syndrome. Acta Neuropathol 93, 50–61 (1997). · DOI
  24. Ruszczycki, B. et al. Sampling issues in quantitative analysis of dendritic spines morphology. BMC Bioinformatics 13, 213 (2012).
  25. Munchau, A. et al. Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. J Neurol Neurosurg Psychiatry 76, 527–533 (2005). · DOI
  26. Chao, H. T., Zoghbi, H. Y. & Rosenmund, C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56, 58–65 (2007). · DOI · Paper page
  27. Blue, M. E., Naidu, S. & Johnston, M. V. Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol 156, 345–352 (1999). · DOI
  28. Johnston, M. V., Blue, M. E. & Naidu, S. Rett syndrome and neuronal development. J Child Neurol 20, 759–763 (2005). · doi:10.1177/08830738050200091101
  29. Roden, W. H., Peugh, L. D. & Jansen, L. A. Altered GABA(A) receptor subunit expression and pharmacology in human Angelman syndrome cortex. Neurosci Lett 483, 167–172 (2010). · DOI
  30. Viemari, J. C. et al. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci 25, 11521–11530 (2005). · DOI · Paper page
  31. Rogoz, Z., Skuza, G. & Legutko, B. Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 56, 661–671 (2005).
  32. de Boer, T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 57 Suppl 4, 19–25 (1996).
  33. Staudacher, I. et al. hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedebergs Arch Pharmacol 383, 119–139 (2011). · DOI
  34. Anttila, S. A. & Leinonen, E. V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7, 249–264 (2001). · DOI · Paper page
  35. Medrihan, L. et al. Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol 99, 112–121 (2008). · DOI · Paper page
  36. Abdala, A. P., Dutschmann, M., Bissonnette, J. M. & Paton, J. F. Correction of respiratory disorders in a mouse model of Rett syndrome. Proc Natl Acad Sci USA 107, 18208–18213 (2010). · DOI · Paper page
  37. Katz, D. M., Dutschmann, M., Ramirez, J. M. & Hilaire, G. Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth. Respir Physiol Neurobiol 168, 101–108 (2009). · DOI · Paper page
  38. Rogoz, Z., Wrobel, A., Dlaboga, D., Maj, J. & Dziedzicka-Wasylewska, M. Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. J Physiol Pharmacol 53, 105–116 (2002).
  39. Lee, M. M., Reif, A. & Schmitt, A. G. Major depression: a role for hippocampal neurogenesis? Curr Top Behav Neurosci 14, 153–179 (2013). · DOI
  40. Devoto, P., Flore, G., Pira, L., Longu, G. & Gessa, G. L. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur J Pharmacol 487, 105–111 (2004). · DOI
  41. Williams, E. C. et al. Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet 23, 2968–2980 (2014). · DOI · Paper page
  42. Calfa, G., Percy, A. K. & Pozzo-Miller, L. Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp Biol Med (Maywood) 236, 3–19 (2011). · DOI
  43. Ranjan, A. & Mallick, B. N. A modified method for consistent and reliable Golgi-cox staining in significantly reduced time. Front Neurol 1, 157 (2010). · DOI
  44. Harris, K. M., Jensen, F. E. & Tsao, B. Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J Neurosci 12, 2685–2705 (1992). · DOI · Paper page
  45. Miledi, R., Palma, E. & Eusebi, F. Microtransplantation of neurotransmitter receptors from cells to Xenopus oocyte membranes: new procedure for ion channel studies. Methods Mol Biol 322, 347–355 (2006). · DOI
  46. Miledi, R., Parker, I. & Sumikawa, K. Synthesis of chick brain GABA receptors by frog oocytes. Proc R Soc Lond B Biol Sci 216, 509–515 (1982). · doi:10.1098/rspb.1982.0089

Cited by

See all 58

Metadata

Authors
Bittolo, T., Raminelli, C. A., Deiana, C., Baj, G., Vaghi, V., Ferrazzo, S., Bernareggi, A., & Tongiorgi, E.
Venue
Scientific Reports
Published
2016-01-25
Volume
6
Issue
1
ISSN
2045-2322
Cited by
58
References
14
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.